.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The BLISS-52 randomized trial provided pivotal evidence for belimumab, a monoclonal antibody targeting the B-lymphocyte stimulator pathway, in active systemic lupus erythematosus receiving standard therapy. Belimumab improved the proportion of patients achieving a defined composite response compared with placebo, supporting biologic therapy as an additional option for selected patients with active disease. For internists, the study is relevant because SLE often presents with multisystem symptoms and can be difficult to distinguish from infection, drug effects or other autoimmune conditions. Treatment decisions should therefore be phenotype-driven and balanced against organ involvement, disease severity and infection risk. Belimumab is not a replacement for urgent high-intensity immunosuppression when there is immediately organ-threatening disease. Instead, it can form part of longer-term disease control in appropriate patients. The broader lesson is that SLE management increasingly requires targeted therapy combined with careful monitoring and steroid-sparing strategies. A structured approach to vaccination, infection screening, reproductive planning and cardiovascular risk is essential because long-term outcomes depend on much more than lupus activity alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The BLISS-52 randomized trial provided pivotal evidence for belimumab, a monoclonal antibody targeting the B-lymphocyte stimulator pathway, in active systemic lupus erythematosus receiving standard therapy. Belimumab improved the proportion of patients achieving a defined composite response compared with placebo, supporting biologic therapy as an additional option for selected patients with active disease. For internists, the study is relevant because SLE often presents with multisystem symptoms and can be difficult to distinguish from infection, drug effects or other autoimmune conditions. Treatment decisions should therefore be phenotype-driven and balanced against organ involvement, disease severity and infection risk. Belimumab is not a replacement for urgent high-intensity immunosuppression when there is immediately organ-threatening disease. Instead, it can form part of longer-term disease control in appropriate patients. The broader lesson is that SLE management increasingly requires targeted therapy combined with careful monitoring and steroid-sparing strategies. A structured approach to vaccination, infection screening, reproductive planning and cardiovascular risk is essential because long-term outcomes depend on much more than lupus activity alone.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
